Effect of lacidipine on blood pressure and endothelial function in mild-to-moderate essential hypertension patients with diabetes in Korea

Korean Circulation Journal

Volumn 40, Issue 12, 2010, Pages 632-638

  Kim, Dae Hee ^a,s   Oh, Il Young ^a   Lee, Hae Young ^a   Kim, Yong Jin ^a   Kim, Hyo Soo ^a   Kim, Cheol Ho ^a   Oh, Byung Hee ^a   Kim, Kwon Sam ^b   Kim, Doo Il ^c   Kim, Young Dae ^d   Ryu, Kyu Hyung ^e   Park, Si Hoon ^f   Baek, Sang Hong ^g   Shin, Dong Gu ^h   Shim, Wan Joo ⁱ   Ahn, Tae Hoon ^j   Oh, Seok Kyu ^k   Lee, Seung Hwan ^l   Lee, Sung Yun ^m   Jeong, Myung Ho ⁿ   Chung, Wook Sung ^g   Jeong, Jun Young ^o   Choi, So Yeon ^p   Choi, Si Wan ^q   Hyon, Min Su ^r   more..

^a Seoul National University College of Medicine   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

^c Inje University College of Medicine   (South Korea)

^d Dong A University College of Medicine   (South Korea)

^e Konkuk University School of Medicine   (South Korea)

^f Ewha Womans University   (South Korea)

^g The Catholic University of Korea College of Medicine   (South Korea)

^h Yeungnam University College of Medicine   (South Korea)

ⁱ Korea University College of Medicine   (South Korea)

^j Gachon University   (South Korea)

^k Wonkwang University   (South Korea)

^l Wonju Severance Christian Hospital   (South Korea)

^m Inje University College of Medicine   (South Korea)

ⁿ Chonnam National University Medical School   (South Korea)

^o Eulji University   (South Korea)

^p Ajou University School of Medicine   (South Korea)

^q Chungnam National University College of Medicine   (South Korea)

^r Soonchunhyang University College of Medicine   (South Korea)

^s University of Ulsan College of Medicine   (South Korea)

more..

Author keywords

Diabetes mellitus; Endothelium; Hypertension; Lacidipine

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANTACID AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BIGUANIDE; C REACTIVE PROTEIN; GELATINASE B; GLYCERYL TRINITRATE; LACIDIPINE; MONOCYTE CHEMOTACTIC PROTEIN 1; ORAL ANTIDIABETIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; SULFONYLUREA;

ADULT; ARTERY ENDOTHELIUM; ARTICLE; BACKACHE; BIOCHEMISTRY; BLADDER CANCER; BLOOD LEVEL; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BORDERLINE HYPERTENSION; BRAIN HEMORRHAGE; CLINICAL TRIAL; DEPRESSION; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; ESSENTIAL HYPERTENSION; FEMALE; HEART PALPITATION; HEMORRHOID; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; KOREA; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; MONOCYTE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PROSTATE HYPERTROPHY; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; TREATMENT DURATION; VASODILATATION;

EID: 79551696061     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2010.40.12.632     Document Type: Article

References (30)

1. Arauz-Pacheco C, Parrott MA, Raskin P. Treatment of hypertension in adults with diabetes. Diabetes Care 2003;26(Suppl 1):S80-2.
2. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72. (Pubitemid 37430158)
3. Kim KI, Kim Y, Kim HJ, et al. Current status and characteristics of hypertension treatment by primary physicians in Korea: data from Korean Epidemiology Study on Hypertension (KEY Study). Am J Hypertens 2008;21:884-9.
4. Sowers JR, Haffner S. Treatment of cardiovascular and renal risk factors in the diabetic hypertensive. Hypertension 2002;40:781-8. (Pubitemid 35434893)
5. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs 2002;62:265-84. (Pubitemid 34169434)
6. Zanchetti A, Bond MG, Hennig M, et al. Absolute and relative changes in carotid intima-media thickness and atherosclerotic plaques during long-term antihypertensive treatment: further results of the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2004;22:1201-12. (Pubitemid 38721012)
7. Zanchetti A, Bond MG, Hennig M, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002;106:2422-7.
8. Frattola A, Parati G, Castiglioni P, et al. Lacidipine and blood pressure variability in diabetic hypertensive patients. Hypertension 2000;36:622-8.
9. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-65. (Pubitemid 34084631)
10. Salako BL, Kadiri S, Walker O, Fehintola FA. Evaluation of lacidipine (a calcium blocker) in the treatment of hypertension in black African people: a double-blind comparison with hydrochlorothiazide. Afr J Med Med Sci 1998;27:73-5.
11. Tcherdakoff P. French large-scale study evaluating the tolerability and efficacy of lacidipine. J Cardiovasc Pharmacol 1995;25(Suppl 3):S27-32.
12. Kim DH, Oh SI, Kim YK, Choi SW, Yoo WS. Efficacy and safety of nifedipine gastrointestinal therapeutic system (Adalat OROS) in patients with mild to moderate essential hypertension. Korean Circ J 1992;22:488-93.
13. Choi YJ, Lee MM, Choe SJ, et al. A randomized, double-blind clinical trial to determine the efficacy of carvedilol vs. atenolol in patients with stage 1 to 2 essential hypertension. Korean Circ J 1998;28:359-65.
14. Jin SB, Rhee YW, Chang SW, Kim KC, Kim SP, Song CS. Effects of dihydrochlorothiazide, propranolol, and prazosin on serum lipids in patients with essential hypertension. Korean Circ J 1985;15:329-36.
15. Cheong HJ, Kang HS, Choue CW, et al. Antihypertensive effects and safety of isradipine in patients with essential hypertension. Korean Circ J 1993;23:741-9.
16. Park SW, Doo YC, Kim WH, et al. Amlodipine monotherapy in patients with mild to moderate essential hypertension. Korean Circ J 1992;22:852-7.
17. Pieper GM, Gross GJ. Oxygen free radicals abolish endothelium-dependent relaxation in diabetic rat aorta Am J Physiol 1988;255:H825-33.
18. Tesfamariam B, Cohen RA. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol 1992;263:H321-6.
19. Dai FX, Diederich A, Skopec J, Diederich D. Diabetes-induced endothelial dysfunction in streptozotocin-treated rats: role of prostaglandin endoperoxides and free radicals. J Am Soc Nephrol 1993;4:1327-36.
20. Yugar-Toledo JC, Tanus-Santos JE, Sabha M, et al. Uncontrolled hypertension, uncompensated type II diabetes, and smoking have different patterns of vascular dysfunction. Chest 2004;125:823-30. (Pubitemid 38367270)
21. Balletshofer BM, Goebbel S, Rittig K, et al. Intense cholesterol lowering therapy with a HMG-CoA reductase inhibitor does not improve nitric oxide dependent endothelial function in type-2-diabetes: a multicenter, randomised, double-blind, three-arm placebo-controlled clinical trial. Exp Clin Endocrinol Diabetes 2005;113:324-30. (Pubitemid 40896006)
22. Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 1995;346:467-71.
23. Economides PA, Caselli A, Tiani E, Khaodhiar L, Horton ES, Veves A. The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. J Clin Endocrinol Metab 2004;89:740-7. (Pubitemid 38269887)
24. Guerci B, Bohme P, Kearney-Schwartz A, Zannad F, Drouin P. Endothelial dysfunction and type 2 diabetes: part 2. altered endothelial function and the effects of treatments in type 2 diabetes mellitus. Diabetes Metab 2001;27:436-47. (Pubitemid 32852452)
25. Braunersreuther V, Mach F, Steffens S. The specific role of chemokines in atherosclerosis. Thromb Haemost 2007;97:714-21.
26. Sardo MA, Campo S, Mandraffino G, et al. Tissue factor and monocyte chemoattractant protein-1 expression in hypertensive individuals with normal or increased carotid intima-media wall thickness. Clin Chem 2008;54:814-23. (Pubitemid 351671606)
27. Bae JH, Bassenge E, Lim DM, Synn YC, Kim KY, Schwemmer M. Effects of lacidipine on vascular responses in patients with coronary artery disease. Int J Cardiol 2005;101:377-83. (Pubitemid 40719973)
28. Koh KK, Han SH, Chung WJ, et al. Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. Am J Cardiol 2004;93:1432-5, A10.
29. Juhan-Vague I, Alessi MC, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med 1996;28:371-80. (Pubitemid 26268257)
30. Kaikita K, Fogo AB, Ma L, Schoenhard JA, Brown NJ, Vaughan DE. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation 2001;104:839-44. (Pubitemid 32762685)